Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D F Murrell

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
The British Journal of Dermatology|May 14, 2013
A quantitative approach to histopathological dissection of elastin-related disorders using multiphoton microscopyP L Tong, J Qin, C L Cooper, et al.
Clinical and Experimental Dermatology|August 21, 2008
Clinical heterogeneity in recessive epidermolysis bullosa due to mutations in the keratin 14 gene, KRT14E Yiasemides, N Trisnowati, J Su, et al.
The British Journal of Dermatology|April 21, 2015
A pilot comparison study of four clinician-rated atopic dermatitis severity scalesC Y Zhao, A Q T Tran, J P Lazo-Dizon, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 12, 2021
Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B studyJ I Silverberg, A Pinter, A Alavi, et al.
The British Journal of Dermatology|June 14, 2005
Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trialA B Gottlieb, C E M Griffiths, V C Ho, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 21, 2019
Inter-rater reliability of the BIOCHIP indirect immunofluorescence dermatology mosaic in bullous pemphigoid and pemphigus patientsA Yang, R R Xuan, W Melbourne, et al.
The British Journal of Dermatology|September 3, 2017
Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statementA M Drucker, K Eyerich, M S de Bruin-Weller, et al.
The British Journal of Dermatology|October 10, 2013
The development and validation of the treatment of autoimmune bullous disease quality of life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering diseaseA Tjokrowidjaja, B S Daniel, J W Frew, et al.
The British Journal of Dermatology|May 4, 2021
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE studyD F Murrell, A Patsatsi, P Stavropoulos, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 31, 2024
Autoimmune blistering diseases treated with glucocorticoids: An international study of steroid-induced myopathyA He, B Koszegi, S Uzun, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
The British Journal of Dermatology|May 14, 2013
A quantitative approach to histopathological dissection of elastin-related disorders using multiphoton microscopyP L Tong, J Qin, C L Cooper, et al.
Clinical and Experimental Dermatology|August 21, 2008
Clinical heterogeneity in recessive epidermolysis bullosa due to mutations in the keratin 14 gene, KRT14E Yiasemides, N Trisnowati, J Su, et al.
The British Journal of Dermatology|April 21, 2015
A pilot comparison study of four clinician-rated atopic dermatitis severity scalesC Y Zhao, A Q T Tran, J P Lazo-Dizon, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 12, 2021
Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B studyJ I Silverberg, A Pinter, A Alavi, et al.
The British Journal of Dermatology|June 14, 2005
Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trialA B Gottlieb, C E M Griffiths, V C Ho, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 21, 2019
Inter-rater reliability of the BIOCHIP indirect immunofluorescence dermatology mosaic in bullous pemphigoid and pemphigus patientsA Yang, R R Xuan, W Melbourne, et al.
The British Journal of Dermatology|September 3, 2017
Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statementA M Drucker, K Eyerich, M S de Bruin-Weller, et al.
The British Journal of Dermatology|October 10, 2013
The development and validation of the treatment of autoimmune bullous disease quality of life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering diseaseA Tjokrowidjaja, B S Daniel, J W Frew, et al.
The British Journal of Dermatology|May 4, 2021
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE studyD F Murrell, A Patsatsi, P Stavropoulos, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 31, 2024
Autoimmune blistering diseases treated with glucocorticoids: An international study of steroid-induced myopathyA He, B Koszegi, S Uzun, et al.
Pageof 6